Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation.

Laboratorio de Investigaciones Biomédicas, Departamento de Fisiología and Hospital Universitario Virgen del Rocío, Universidad de Sevilla, 41013 Sevilla, Spain.
Journal of Neuroscience (Impact Factor: 6.75). 05/2005; 25(16):4091-8. DOI: 10.1523/JNEUROSCI.4312-04.2005
Source: PubMed

ABSTRACT Glial cell line-derived neurotrophic factor (GDNF) exerts a notable protective effect on dopaminergic neurons in rodent and primate models of Parkinson's disease (PD). The clinical applicability of this therapy is, however, hampered by the need of a durable and stable GDNF source allowing the safe and continuous delivery of the trophic factor into the brain parenchyma. Intrastriatal carotid body (CB) autografting is a neuroprotective therapy potentially useful in PD. It induces long-term recovery of parkinsonian animals through a trophic effect on nigrostriatal neurons and causes amelioration of symptoms in some PD patients. Moreover, the adult rodent CB has been shown to express GDNF. Here we show, using heterozygous GDNF/lacZ knock-out mice, that unexpectedly CB dopaminergic glomus, or type I, cells are the source of CB GDNF. Among the neural or paraneural cells tested, glomus cells are those that synthesize and release the highest amount of GDNF in the adult rodent (as measured by standard and in situ ELISA). Furthermore, GDNF expression by glomus cells is maintained after intrastriatal grafting and in CB of aged and parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated animals. Thus, glomus cells appear to be prototypical abundant sources of GDNF, ideally suited to be used as biological pumps for the endogenous delivery of trophic factors in PD and other neurodegenerative diseases.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The endogenous reparative capacity of the adult human brain is low and chronic neurodegenerative disorders of the central nervous system represent one of the greatest areas of unmet clinical need in the developing world. Novel therapeutic strategies to treat them include (i) growth factor delivery to boost endogenous repair and (ii) replacement cell therapy, including dopaminergic neurons for Parkinson's Disease (PD). However these approaches are limited not only by rapid degradation of growth factors, but also by the poor availability and survival of implanted cells that lack the necessary stromal support. We therefore hypothesised that provision of a transient artificial stroma for paracrine delivery of pro-survival factors may overcome both of these issues. Using leukaemia inhibitory factor (LIF) - a proneural, reparative cytokine - formulated as target-specific PLGA nano-particles (LIF-nano) - we discovered that attachment of LIF-nano to freshly isolated fetal dopaminergic cells improved their survival fourfold: furthermore, in vivo, the numbers of surviving human fetal dopaminergic cells tended to be higher at 3 months after grafting into the striatum of nude rats. In addition we also analysed the effect of a novel nano-stroma incorporating XAV939, a potent inhibitor of the developmentally important wnt/β-catenin signalling pathway, to investigate whether it could also promote the survival and differentiation of human fetal dopaminergic precursors and found both TH+ neurons and total neurons were increased in number. This is the first demonstration that LIF-nano-stroma, and XAV-nano-stroma, each have pro-survival effects on human dopaminergic neurons, with potential value for target-specific modulation of neurogenic fate in cell based therapies for PD.
    Disease Models and Mechanisms 08/2014; · 5.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The carotid body (CB) is a small neural crest-derived structure that senses oxygen levels in blood and monitors ventilation. The spontaneously hypertensive rat (SHR) is considered a good experimental model for primary hypertension and is extensively used to study cardiovascular diseases. The hypertensive CB shows structural plasticity and could enlarge without vasodilation. Our immunohistochemical studies revealed the presence of nuclear Ki-67 protein in the sustentacular cells, nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and their corresponding receptors p75NTR, TrkA, TrkB and TrC in the majority of glomus cells and also in a subset of sustentacular cells. In addition, virtually all glomus cells expressed glial cell line-derived neurotrophic factor and its specific receptor GFRα1. The present study demonstrates that in glomus cells of hypertensive animals there is enhanced expression of components of the neurotrophin signaling system compared to normotensive rats. Our results suggest that the elevated production of neurotrophic factors in SHRs could explain CB and sympathetic hyperactivity leading to hypertension.
    Respiratory Physiology & Neurobiology 10/2014; · 1.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cells that constitute the sympathetic nervous system originate from the neural crest. This review addresses the current understanding of sympathetic ganglion development viewed from molecular and morphological perspectives. Development of the sympathetic nervous system is categorized into three main steps, as follows: (1) differentiation and migration of cells in the neural crest lineage for formation of the primary sympathetic chain, (2) differentiation of sympathetic progenitors, and (3) growth and survival of sympathetic ganglia. The signaling molecules and transcription factors involved in each of these developmental stages are elaborated mostly on the basis of the results of targeted mutation of respective genes. Analyses in mutant mice revealed differences between the superior cervical ganglion (SCG) and the other posterior sympathetic ganglia. This review provides a summary of the similarities and differences in the development of the SCG and other posterior sympathetic ganglia. Relevant to the development of sympathetic ganglia is the demonstration that neuroendocrine cells, such as adrenal chromaffin cells and carotid body glomus cells, share a common origin with the sympathetic ganglia. Neural crest cells at the trunk level give rise to common sympathoadrenal progenitors of sympathetic neurons and chromaffin cells, while progenitors segregated from the SCG give rise to glomus cells. After separation from the sympathetic primordium, the progenitors of both chromaffin cells and glomus cells colonize the anlage of the adrenal gland and carotid body, respectively. This review highlights the biological properties of chromaffin cells and glomus cells, because, although both cell types are derivatives of sympathetic primordium, they are distinct in many respects.
    Cell and Tissue Research 04/2014; · 3.33 Impact Factor


Available from
May 28, 2014